Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178 is registered in ClinicalTrials.gov with University of Texas at Austin as lead sponsor.

NCT NCT06132178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
Lead sponsor
University of Texas at Austin
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder, mdd, recurrent depression, treatment resistant depression